Epclusa patent date?

Epclusa (ombitasvir/paritaprevir/ritonavir + dasabuvir) – Patent “life” overview

What does this mean for patients and prescribers?

1. Patent expirations are staggered.
   The earliest expiry is the ombitasvir patent (2021), followed by paritaprevir (2024) and then the combination/ dasabuvir patents (2027). This means that generic manufacturers could start filing applications for each component or the combination as those patents mature.

2. Patent life is 20 years from the filing date.
   The U.S. system grants a 20‑year term (plus adjustments for regulatory delay). The dates above are calculated from the original filing dates.

3. Multiple patents cover the drug.
   Even after one patent expires, other patents can still provide protection. For example, once the ombitasvir patent ends, the paritaprevir and dasabuvir patents still shield the combination.

4. Possible patent challenges.
   Gilead’s patents are occasionally challenged in courts. A successful challenge could shorten the exclusivity period, but such cases take years to resolve.

5. Global differences.
   In the European Union, the primary patents for Epclusa expire between 2022 and 2025, depending on the specific claim. In other jurisdictions, expiration dates vary according to local filing dates and term adjustments.

Bottom line

• Short‑term: The first patent (ombitasvir) expired in March 2021; generic filings for this component may be underway in some markets.
• Mid‑term: The paritaprevir patent will expire in late 2024, opening the door for generic paritaprevir and potentially generic combination products thereafter.
• Long‑term: The combination patents and dasabuvir patent hold until 2027, after which the entire Epclusa product will likely enter the generics arena.

If you’re a clinician, pharmacist, or a patient planning ahead, keep an eye on FDA approvals for generic Epclusa. These dates are approximate; for the most accurate, consult the current USPTO or EMA patent databases.